10.02.2024

Romanian drug manufacturer Antibiotice Iasi has a RON850 million investment plan until 2030, covered through a funding mix, made up of cohesion funds, state aid, PNRR funds and EIB loan, stated more

08.14.2024

Romanian-owned drug manufacturer Antibiotice Iasi (stock symbol: ATB) ended the first half of 2024 with net profit of RON74 million, up 20% on the year, while its revenue rose by 8% to RON380 million, more

05.15.2024

Antibiotice Iasi, the largest Romanian-owned drug manufacturer, saw revenues reach an overall RON192.5 million level, 13% higher than in the year-earlier period. more

04.30.2024

Antibiotice Iasi, the largest Romanian-held drug maker, has a total RON850 million investment plan between 2023-2030 to reach RON1 billion turnover at the end of this period. more

03.28.2024

Pharma manufacturer Antibiotice Iasi has commissioned a 2.5 MW photovoltaic plant, with total investments in the project amounting to RON11.8 million, of which RON4.07 million were granted by the more

03.25.2024

Antibiotice Iasi, the biggest Romanian-held drug manufacturer, wants to reach RON104 million net profit in 2024, up 28% from 2023, in line with its income and expenses budget. more

03.14.2024

Pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) is summoning its shareholders to approve, among others, the distribution of RON31 million from the company's 2023 profit under the form of more

02.28.2024

Pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) ended 2023 with net profit of RON80.7 million, up 109.5% from 2022, and a turnover of RON600.8 million, up 7.2% on the year, in line with more

02.09.2024

Antibiotice Iasi, the largest Romanian-held pharma producer, is launching eight veterinary products in the range of nutritional supplements, complementing the company’s veterinary prescription more

01.25.2024

The Board of Directors of pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) announced in a stock market report on Thursday (Jan. 25, 2024) that it has called shareholders for a meeting on February more

11.16.2023

The Bucharest Stock Exchange has announced Wednesday evening that the shares of Antibiotice (ATB.RO), the Romanian manufacturer of generic drugs, listed on the local capital market for 26 years, will more

11.15.2023

Romanian state-owned pharma producer Antibiotice Iasi for the first nine months of 2023 reported RON463.4 million turnover, up 28%, and RON76 million net profit, more than doubled the RON30 million more

10.31.2023

The extraordinary general meeting of shareholders convened by drug maker Antibiotice Iasi on October 30 approved the signing of a financing contract worth EUR25 million euro, i.e. RON23 million more

10.05.2023

Antibiotic Iasi, the biggest Romanian-held drug producer, is mulling new export markets, including Nordic ones, where it is trying to already develop its first local partnerships. more

09.16.2023

Romanian state-owned pharmaceutical manufacturer Antibiotice (ATB.RO) has called shareholders for a general meeting on October 30, 2023 to secure approval for the conclusion of a financing contract more

05.18.2023

Antibiotice Iasi (ATB.RO), Romania’s most important generic drug manufacturer, on Thursday (May 18) informed the Bucharest Stock Exchange (BVB) that SIF Oltenia (SIF5.RO), its second largest more

05.12.2023

Romanian pharma producer Antibiotice Iasi ended the first quarter of 203 with RON178 million sales, up around 40%, and RON22 million net profit, almost triple the level of the year-earlier period. more

02.27.2023

Romanian pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) said in a stock market report on Monday (Feb 27) that it ended 2022 with a net profit of RON38.5 million in 2022. up 28.6% versus 2021, more

01.18.2023

Romanian pharmaceutical producer Antibiotice Iasi has budgeted RON580 million revenues for 2023, up 11% year-on-year and RON42 million net profit, 10% higher than in 2022. more

12.13.2022

Enel X Romania, part of Enel X Global Retail, the advanced energy services division of Italy’s Enel Group, will build a photovoltaic (PV) park with a total installed capacity of 2.5 MW for Romanian more

12.09.2022

Romanian pharmaceutical manufacturer Antibiotice Iasi is opening a new plant, in the wake of a EUR20 million investment, with a 50% higher production capacity than the existing unit. more

11.11.2022

Romanian pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) said in a stock market report on Friday that it ended the first nine months of 2022 with sales revenue of RON361.7 million, up 47% on the more

10.06.2022

Romanian drug maker Antibiotice Iasi has budgeted RON300 million investments for the following years. more

05.13.2022

Antibiotice Iasi (ATB.RO), the biggest Romanian-held drug maker, reported a net profit net of RON8.6 million for the first three months of 2022, up 113.7% from the year-earlier period, in line with more

01.31.2022

Antibiotice Iasi (ATB.RO), the biggest local Romanian-held drug producer, projects total revenues worth RON448 million in 2022, up 15% on the year and net profit of RON32 million, 6% higher than in more